Gateway Bio, Inc.
Publicly observedDurham, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Durham | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Gateway Bio, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | MLZ9QD9YXCN7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant23 Sept 2025Publicly observed
NIH SBIR/STTR award: Next Generation Stealth Lipid for the Delivery of mRNA
USD 314,347.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2025Publicly observed
NIH SBIR/STTR award: Novel Stealth Lipid for use in HIV MPER Vaccine
USD 303,173.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant16 Jul 2020Publicly observed
NIH SBIR/STTR award: Scale-up and Toxicity Studies of POEGMA-Uricase
USD 735,254.00 · National Center for Advancing Translational Sciences · Source: NIH RePORTER (opens in a new tab)
- Grant16 Jul 2020Publicly observed
NIH SBIR/STTR award: Scale-up and Toxicity Studies of POEGMA-Uricase
USD 639,413.00 · National Center for Advancing Translational Sciences · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.